Published: July 30, 2010
Complete Genomics, Inc. Files Registration Statement for Proposed Initial Public Offering
MOUNTAIN VIEW, Calif. - (BUSINESS WIRE) - Complete Genomics, Inc. announced today that it has filed a registration
statement on Form S-1 with the U.S. Securities and Exchange Commission
("SEC" ) relating to the proposed initial public offering of shares of
its common stock. The shares of common stock to be sold in this offering
are proposed to be sold solely by Complete Genomics, Inc.
UBS Investment Bank and Jefferies & Company will be acting as joint
book-running managers, with Baird and Cowen and Company acting as
co-managers for the offering. This offering will be made only by means
of a prospectus. Copies of the preliminary prospectus for this offering
may be obtained, when available, from the prospectus department of UBS
Investment Bank at 299 Park Avenue, New York, NY 10171, Attention:
Prospectus Department, or via telephone at (888) 827-7275, or from the
prospectus department of Jefferies & Company at 520 Madison Avenue, New
York, NY 10022, Attention: Syndicate Prospectus Department, or via
telephone at (888) 449-2342.
A registration statement relating to these securities has been filed
with the SEC but has not yet become effective. These securities may not
be sold, nor may offers to buy be accepted, prior to the time the
registration statement becomes effective. This press release shall
neither constitute an offer to sell nor a solicitation of an offer to
buy nor shall there be any sale of these securities in any state in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state.
About Complete Genomics
Complete Genomics is a life sciences company that has developed and
commercialized an innovative DNA sequencing platform. The Complete
Genomics Analysis Platform (CGA Platform) combines Complete Genomics'
proprietary human genome sequencing technology with our advanced
informatics and data management software. We offer this solution as an
innovative, end-to-end, outsourced service and provide customers with
data that is immediately ready to be used for genome-based research.
Complete Genomics, Inc.
Investor Relations
Scott Sandler,
650-943-2788
ssandler@completegenomics.com
or
Complete
Genomics, Inc.
Vice President of Marketing
Jennifer Turcotte,
650-943-2846
jturcotte@completegenomics.com
Copyright © 2012, Business Wire, Inc., All rights reserved.
Copyright © 2012, NewsBlaze,
Daily News
Search News
Daily News
